Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response

Journal of Clinical Oncology

Volumn 30, Issue 10, 2012, Pages 1144-1145

  White, Deborah L ^a   Hughes, Timothy P ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ORGANIC CATION TRANSPORTER 1;

CANCER CLASSIFICATION; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; EVENT FREE SURVIVAL; HUMAN; LETTER; MUTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84861454645     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.1090     Document Type: Letter

References (17)

1. Marin D, Ibrahim AR, Lucas C, et al: Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232-238, 2011
2. White DL, Saunders VA, Dang P, et al: Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064-4072, 2007 (Pubitemid 350248463)
3. White DL, Saunders VA, Dang P, et al: CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose: Those with high OCT-1 activity have excellent responses on either dose-A TOPS Correlative Study. Presented at the American Society of Haematology annual meeting, San Francisco, CA, December 6-9, 2008
4. White DL, Saunders VA, Dang P, et al: OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia 24:1962-1965, 2010
5. White DL, Dang P, Engler J, et al: Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28:2761-2767, 2011
6. Hughes TP, Branford S, White DL, et al: Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112:3965-3973, 2008
7. Crossman LC, Druker BJ, Deininger MW, et al: hOCT 1 and resistance to imatinib. Blood 106:1133-1134, 2005
8. Thomas J, Wang L, Clark RE, et al: Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 104:3739-3745, 2004 (Pubitemid 39564452)
9. Cilloni D, Messa F, Gottardi E, et al: Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 101:979-988, 2004
10. White D, Saunders V, Grigg A, et al: Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 25:4445-4451, 2007 (Pubitemid 350013851)
11. White D, Saunders V, Lyons AB, et al: In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106:2520-2526, 2005 (Pubitemid 41510828)
12. Sokal JE, Cox EB, Baccarani M, et al: Prognostic discrimination in "goodrisk"chronic granulocytic leukemia. Blood 63:789-799, 1984 (Pubitemid 14141296)
13. Hasford J, Pfirrmann M, Hehlmann R, et al: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850-858, 1998 (Pubitemid 28280552)
14. Picard S, Titier K, Etienne G, et al: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496-3499, 2007 (Pubitemid 46572540)
15. Larson RA, Druker BJ, Guilhot F, et al: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 111:4022-4028, 2008
16. Marin D, Bazeos A, Mahon FX, et al: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381-2388, 2011
17. Esposito N, Colavita I, Quintarelli C, et al: SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood 118:3634-3644, 2011